[A case of cavitating pneumococcal pneumonia developed during the treatment with etanercept for rheumatoid arthritis].
A 54-year-old woman who had been treated for rheumatoid arthritis (RA) with the anti-TNF-alpha drug, etanercept, was referred to our department on 27 April 2006 because of dyspnea and shock. Chest X-ray and computed tomography on admission indicated bilateral pneumonia which was proved to be caused by Streptococcus pneumoniae with positive blood culture results. The patient had recovered from multiple organ failure with intensive treatments such as NIPPV and cardiovascular support with cathecolamines, however, the left upper lobe of her lung had developed a large cavity that had been producing viable pneumococci on sputum culture for more than one month. As the development of lung necrosis and subsequent formation of a cavity is rare in patients with pneumococcal pneumonia, this case should be noted in terms of the relevance of both the fulminating pathogenecity of Streptococcus pneumoniae and the anti TNF-alpha drug treatment.
Kida
Yoko
Y
Department of Respiratory Medecine, Kobe City Medical Center General Hospital.
Harada
Yuka
Y
Tachikawa
Ryo
R
Hata
Akito
A
Kaji
Reiko
R
Takeshima
Yoshimi
Y
Hayashi
Michio
M
Nishimura
Takashi
T
Tomii
Keisuke
K
Katakami
Nobuyuki
N
Ishihara
Kyosuke
K
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011018:Pneumonia, Pneumococcal / Q000209:etiology*; D018124:Receptors, Tumor Necrosis Factor
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept